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Abstract: OBJECTIVE The aim of the study was to analyze the expression, regulation and role of
microRNA-125b (miR-125b) in systemic sclerosis (SSc). METHODS MiR-125b expression was assessed
by qPCR on RNA from dermal fibroblasts and whole skin biopsies of healthy controls (HC) and SSc
patients. To identify downstream effectors, RNA from HC fibroblasts after miR-125b knockdown was
sequenced and further validated using qPCR and Western blot. Fibrosis, apoptosis and proliferation were
assessed by Caspase-Glo 3/7 assay, Western blot, immunofluorescence for cleaved caspase 3 and Annexin
V live assay in dermal fibroblasts. RESULTS Expression of miR-125b was significantly downregulated in
SSc skin biopsies by 53% (median 0.47, Q 0.35, 0.69; p<0.001) and in SSc dermal fibroblasts by 47% (me-
dian 0.53, Q 0.36, 0.58; p<0.001) in comparison to HC skin biopsies and fibroblasts, respectively (n=10,
each). Treatment with the histone deacetylase inhibitors trichostatin A and tubastatin significantly de-
creased the expression of miR-125b in dermal fibroblasts. MiR-125b knockdown significantly reduced
cell proliferation and ฀SMA expression at RNA and protein levels. RNAseq identified BAK1, BMF and
BBC3 as potential targets of miR-125b. qPCR confirmed that knockdown of miR-125b upregulated these
genes (n=12, p<0.01). BAK1 showed the strongest induction confirmed on protein level (n=10, p<0.01).
Consequently, miR-125b knockdown increased apoptosis compared to scrambled controls. Accordingly,
miR-125b overexpression decreased apoptosis. CONCLUSION MiR-125b is downregulated in SSc skin
and primary SSc dermal fibroblasts. MiR-125b downregulation increases apoptosis, decreases prolifera-
tion and ฀SMA expression in dermal fibroblasts indicating a compensatory, anti-fibrotic mechanism as a
potential novel therapeutic option. This article is protected by copyright. All rights reserved.
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ABSTRACT  
Objective: The aim of the study was to analyze the expression, regulation and role of 
microRNA-125b (miR-125b) in systemic sclerosis (SSc). 
Methods: MiR-125b expression was assessed by qPCR on RNA from dermal fibroblasts and 
whole skin biopsies of healthy controls (HC) and SSc patients. To identify downstream 
effectors, RNA from HC fibroblasts after miR-125b knockdown was sequenced and further 
validated using qPCR and Western blot. Fibrosis, apoptosis and proliferation were assessed 
by Caspase-Glo 3/7 assay, Western blot, immunofluorescence for cleaved caspase 3 and 
Annexin V live assay in dermal fibroblasts. 
Results: Expression of miR-125b was significantly downregulated in SSc skin biopsies by 
53% (median 0.47, Q1,3 0.35, 0.69; p<0.001) and in SSc dermal fibroblasts by 47% (median 
0.53, Q1,3 0.36, 0.58; p<0.001) in comparison to HC skin biopsies and fibroblasts, 
respectively (n=10, each). Treatment with the histone deacetylase inhibitors trichostatin A 
and tubastatin significantly decreased the expression of miR-125b in dermal fibroblasts. MiR-
125b knockdown significantly reduced cell proliferation and SMA expression at RNA and 
protein levels. RNAseq identified BAK1, BMF and BBC3 as potential targets of miR-125b. 
qPCR confirmed that knockdown of miR-125b upregulated these genes (n=12, p<0.01). 
BAK1 showed the strongest induction confirmed on protein level (n=10, p<0.01). 
Consequently, miR-125b knockdown increased apoptosis compared to scrambled controls. 
Accordingly, miR-125b overexpression decreased apoptosis.  
Conclusion: MiR-125b is downregulated in SSc skin and primary SSc dermal fibroblasts. 
MiR-125b downregulation increases apoptosis, decreases proliferation and αSMA expression 
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     Systemic sclerosis (SSc) is a multiorgan, chronic autoimmune disease characterized by 
fibrosis of the skin and internal organs. Skin fibrosis is a strong surrogate of overall disease 
progression and survival with major impact on the physical function and quality of life of the 
patients. Although novel targeted therapies are in advanced clinical development, there is no 
FDA or EMA approved anti-fibrotic therapy available to date(1, 2). 
     In SSc, tissue injury leading to microvascular damage and release of inflammatory factors 
stimulates transforming growth factor beta 1 (TGFβ1) production and differentiation of 
dermal resident fibroblasts into activated myofibroblasts. Myofibroblasts produce excessive 
amounts of extracellular matrix (ECM) such as collagens and fibronectin. Under 
physiological conditions, this process is terminated by reparative mechanisms driving the 
myofibroblasts into apoptosis. In the pathological course of SSc, persistent TGFβ1 signaling 
protects myofibroblasts from apoptosis and facilitates fibrosis(3-5). 
     Apoptosis plays a prominent role in many biological processes including autoimmunity. 
The BCL-2 family of proteins is at the center of the mitochondrial apoptotic pathway and 
consists of pro- and anti-apoptotic members. Their ratio determines whether a cell survives or 
dies(6, 7). The BCL-2 family is divided into three groups by function and structural 
homology: apoptosis-sensitizers (BH3-only proteins such as BMF and PUMA), anti-
apoptotic proteins (e.g. BCL-2) and apoptosis-executors (BAX and BAK)(8). BH3-only 
proteins exert their pro-apoptotic effects via two alternative ways: by neutralizing anti-
apoptotic proteins or by activating directly the apoptosis effectors BAK and BAX(9). 
     MiRs are small non-coding RNAs, which regulate specific target gene expression by 
repressing mRNA translation or by direct degrading of mRNA(10-12). One miR is able to 
repress up to hundreds of genes and one gene can be repressed by several miRs. Such a fine-
tuned powerful machinery is evolutionally developed and is one of the pillars of post-
transcriptional regulation(13). 
     Screening assays with small number of patients suggested that miR-125b might be 
differentially expressed in the skin of patients with SSc compared to healthy controls(14-16). 
In cardiac fibrosis, miR-125b directly affects fibroblast-to-myofibroblasts transition(17). In 
cancer, it may play a dual, tissue-specific role in increasing or decreasing cell apoptosis and 
proliferation(18-20). Therefore, we hypothesized that miR-125b might play an important role 
in the pathophysiology of SSc, and aimed to characterize its differential expression and 
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MATERIALS AND METHODS 
     Patients and biopsy specimens  
    All research on human derived samples was in compliance with the Helsinki Declaration. 
The approval of the local ethics committee was obtained for the Department of 
Rheumatology, University Hospital Zurich, Switzerland (approved ethical application KEK-
ZH-Nr. 2014-0197). 
     Three millimeter punch biopsies were taken from the forearm skin of SSc patients 
(Supplementary Table 1) or healthy controls (Supplementary Table 2) after signed informed 
consent from patients and healthy donors. All patients fulfilled the EULAR/ACR 2013 
classification criteria(21). The subset of the disease was defined according to LeRoy(22). 
Additionally, skin was taken from healthy, uninvolved skin of various surgery sites of donors 
having a condition not related to SSc (e.g. patients for plastic surgery operations) and 
considered to be healthy control skin. Biopsies were divided by half. One half was used for 
fibroblast isolation, the other half for RNA extraction. 
     Cell culture and stimulation experiments  
     Primary human dermal fibroblasts were obtained by outgrowth culture and used at 
passages 4-10 in standard culture conditions as described before(23). Briefly, half of the 
punch biopsy was cut in smaller pieces and distributed on the surface of the culture plate to 
dry and attach to the surface. Low glucose Dulbecco's Modified Eagle Medium (DMEM, 
Sigma-Aldrich) containing 50 U/mL Penicillin and 50 μg/mL Streptomycin (Gibco), 10% 
fetal bovine serum (10% FBS, Gibco) and 100 µM 2-mercaptoethanol (Gibco) (10% DMEM) 
was added and used for culture. Starvation medium containing 1% FBS was used in some 
experiments. Cells were maintained in 5% CO2 humid 37°C incubator with medium change 
every 3-4 days. Cells were split after they reached 90-100% confluence. 
     For stimulation experiments various cytokines and epigenetic stimuli were used, such as: 
TGFβ1 (0.1-10 ng/ml, Peprotech), activin (10 ng/ml, R&D Systems), PDGF (20 ng/ml, 
Peprotech), IL-1β,  -4, -13 and IL-17A (all 10 ng/ml, ImmunoTools), TNFα (10 ng/ml, R&D 
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RNA isolation and quantitative real-time PCR (qPCR)  
     Half of the 3mm punch biopsy was placed into RNAlaterTM solution (ThermoFisher 
Scientific), stored overnight at +4°C to ensure proper penetration of the tissue, then moved to 
-80°C until the extraction. Half of 3mm punch biopsy was homogenized with Minilys by 
Bertin Technologies with 30sec homogenizing/30sec break 3 cycle on ice until the tissue was 
completely homogenized. Homogenates were proceeded to RNA extraction with the Qiagen 
RNeasy Fibrous Tissue kit according to the manufacturer’s protocol including in-column 
DNA digestion. 
     Expression of miR-125b was assessed separately in epidermis and dermis of paraffin-
embedded skin. For this, we manually separated epidermis from dermis and extracted RNA 
separately with RecoverAll
TM
 Total Nucleic Acid Isolation kit (Ambion) following the 
manufacturer’s protocol. 
    For basal microRNA expression analysis, dermal fibroblasts from passage 4 were collected 
and extracted with the Zymo Quick-RNA
TM
 MicroPrep RNA isolation kit, including in-
column DNA digestion. Reverse transcription and qPCR were performed according to Chen 
et al.(24) and described in detail in supplementary file. 
Transfection and RNA sequencing  
     For transfections, we used the following assays: mirVana
TM
 hsa-miR-125b-5p inhibitor 
(Assay ID MH10148 / #4464085) – anti-125b, mirVanaTM miRNA Inhibitor Negative 
Control #1 (#4464077) – anti-scr, mirVanaTM miRNA mimic hsa-miR-125b-5p (Assay ID 
MC10148 / #4464067) – pre-125b and mirVanaTM miRNA mimic Negative Control #1 
(#4464058) – pre-scr, all from ThermoFisher Scientific; for BAK1 knockdown FlexiTube 
GeneSolution (1027416/Cat no GS578 from Qiagen) and respective siRNA negative control 
were used at the concentration 0.4 nM. Cells were transfected according to the RNAiMAX 
transfection procedure with Lipofectamine® RNAiMAX reagent (ThermoFisher Scientific) 
and 100nM RNA final concentration. Functional assays and harvesting cells for RNA or 
proteins were performed 24, 48 and 72 hours after transfection. RNA sequencing methology 
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Western blot, Pro-Collagen Ia1 ELISA and Sircol
TM
 Collagen assay 
     Western blots (WB) were performed using the following primary antibodies: anti-BAK1 
(1:500, ab32327 Abcam), anti-cleaved caspase 3 (1:200, ab2302 Abcam), anti-alpha smooth 
muscle actin (αSMA) (1:1000, A2547 Sigma) and GAPDH as loading control (1:10`000, 
#2118 Cell signaling) according to standard protocols(25). Proteins for cleaved caspase 3 WB 
were harvested 48 hours after transfection and 16 hours of treatment with 2µM of 
staurosporine (STP – apoptosis inducer) (S5921, Sigma). The ImageJ program was used to 
semi-quantify the signal.  
     The human Pro-Collagen Ia1 (Col1a1) ELISA (R&D systems) and Sircol
TM
 (Biocolor Life 
Science Assays) were used to assess collagens’ content in cell supernatants according to 
manufacturers’ protocols. All conditions were done in triplicates. Mean absorbance and 
collagen concentration were calculated using the standard curve. Anti-scr unstimulated cells 
served as controls. All experimental conditions were calculated as fold change to controls.   
Immunofluorescence (αSMA, cleaved caspase 3) 
     For immunofluorescence staining, 2’000 cells were seeded in 8-well glass chamber slides 
(Lab-Tec). On the next day they were transfected with anti-125b or anti-scr controls. 
Furthermore, cells were stimulated with 10ng/ml TGFβ (for αSMA staining) or with 200µM 
(S)-(+)-camptothecin (C9911, Sigma) to stimulate apoptosis (for cleaved caspase 3 staining) 
24 hours after transfection. After respective fixation and blocking, cells were incubated with 
primary anti-αSMA antibody (1:100, A2547 Sigma) for 1 hour at room temperature or anti-
cleaved caspase 3 antibody (1:300, #9661, Cell Signaling) overnight at 4°C. The following 
secondary antibodies were used: goat anti-mouse IgG (H+L), labeled with Alexa Fluor 546 
(1:400, ThermoFisher Scientific) for αSMA staining or goat anti-rabbit IgG (H+L), labeled 
with Alexa Fluor 546 (1:400, ThermoFisher Scientific) for cleaved caspase 3 staining. To 
visualize cell nuclei, slides were counterstained with DAPI. Pictures were taken with the 
Olympus BX53 microscope equipped with a DP80 camera. Confocal pictures for cleaved 
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Caspase Glo
®
 3/7 and Real Time-Glo™ Annexin V assays 
     To assess apoptosis, the Caspase Glo® 3/7 assay (Promega) was used to measure the 
activity of the key effector caspases 3 and 7. Cells were seeded at a density of 2’000 
cells/well in 96-well white-wall plates. On the next day, cells were transfected with anti-125b 
or anti-scr control, and pre-125b or pre-scr control, respectively. Cleaved caspases 3/7 
activity was assessed 24, 48 and 72 hours after transfection. Two hundred µM (S)-(+)-
camptothecin (C9911, Sigma) was added 18 hours before the assay to stimulate apoptosis. 
Caspase-Glo® reagent was distributed to the wells, carefully mixed and left to incubate in the 
dark for 90 minutes at room temperature. Luminescent signals were measured with the 
Synergy HT microplate reader (BioTek).  
     The Real Time-Glo™ Annexin V Apoptosis kit (Promega) was used to assess the 
progression of apoptosis after transfection in real time. Cells were seeded at a density of 
2’000 cells/well in 96-well white-wall plates and were allowed to settle overnight. Twenty-
four hours after transfection, cells were stimulated with 2µM staurosporine (S5921, Sigma, 
apoptosis inducer) and the annexin V signal was recorded every 70 min, between 5 and 16 
hours after apoptosis stimulation.  
     All conditions were done in quadruplicates. The mean luminescence was calculated, and 
anti-scr transfected unstimulated cells served as controls. All experimental conditions were 
calculated as fold change to controls. 
Real time proliferation assay 
     Real-time cell analysis (RTCA) was used to assess the proliferation after anti-125b 
transfection in real time. Cells were seeded in the E-plates® (ACEA Biosciences, San Diego, 
CA), transfected with anti-125b or anti-scrambled control, and stimulated with TGFβ. The 
cell index was measured every half an hour up to one week. The ACEA RT-CES 16× E-Plate 
Station (ACEA Biosciences) was used in the incubator at 37°C and 5% CO2. The RTCA 
software was used to analyze the data. 
Statistical analysis 
     Data are presented as median ± interquartile range. Non-parametric tests (e.g. Mann-
Whitney, Wilcoxon tests, etc.) were used for assessing statistical significance (p<0.05). The 
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RESULTS 
MiR-125b expression and regulation in SSc skin and primary dermal fibroblasts  
     In all analyzed samples, which were obtained from the patients with different disease 
subtypes (diffuse and limited) and different disease duration (1 to 10 years) (Supplementary 
Table 1. Characteristics of SSc patients), miR-125b was consistently downregulated in SSc 
skin biopsies (n=10, median 0.47, Q1,3 0.35, 0.69; p<0.001) compared with HC skin (n=10) 
(Fig. 1A). The related family member miR-125a was not differentially expressed (data not 
shown). Similarly, miR-125b expression was reduced in cultured dermal SSc fibroblasts 
(median 0.53, Q1,3 0.36, 0.58; n=10, p<0.001) compared with HC fibroblasts (n=10) (Fig. 
1B). In addition, the expression of miR-125b was downregulated in both SSc dermis and 
epidermis from paraffin fixed skin compared to healthy donors (Suppl. Fig. 1). Thus, these 
data indicate that miR-125b is consistently downregulated in SSc skin across different disease 
stages, compartments and cell types including fibroblasts.  
     We further showed that key cytokines active in SSc (TGFβ1, TGFβ1+Activin, PDGF, IL-
1β, IL-4, IL-13, IL-17A, TNFα) did not modulate the expression of miR-125b in primary 
dermal fibroblasts (Suppl. Fig. 2 and data not shown). In contrast, trichostatin A (TSA), a 
pan-inhibitor of histone deacetylases (HDAC), downregulated miR-125b expression in a 
time- and dose-dependent manner in SSc and HC fibroblasts (Fig. 1C-F). There was no 
significant effect on the expression of miR-125b after stimulation with valproic acid, an 
inhibitor of class I HDAC (Suppl. Fig. 3). However, tubastatin A (TBA), an inhibitor of class 
II HDAC, downregulated miR-125b in a dose-dependent manner (Fig. 1G-H). TBA 
specifically downregulated miR-125b, but not unrelated miRs, as shown for miR-342 (Fig. 
1I-J). 
     Taken together, the downregulation of mir-125b appeared to be independent from main 
cytokines playing an emergent role in SSc. However, the experiments indicated an epigenetic 
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Role of miR-125b in fibrosis  
     To characterize the functional role of miR-125b in the pathophysiology of SSc, we 
performed targeted inhibition and overexpression using mirVana
TM
 antagomirs and pre-miRs. 
Transfection with anti-125b resulted in more than 99% downregulation of miR-125b 
expression (Suppl. Fig. 4A-B), while transfection with pre-125b caused an average 7.6-fold 
increase in the expression of miR-125b in HC and SSc fibroblasts 24-72 hours post 
transfection (Suppl. Fig. 4C-D). 
     The expression levels of αSMA and collagens I, III, V were analyzed to assess the effect 
of miR-125b downregulation on key fibrotic parameters. There was no change of the 
expression of collagens on the mRNA and protein level after miR-125b downregulation with 
or without TGFβ1 stimulation in HC and SSc fibroblasts (Suppl. Fig. 5A-H). TGFβ1 
stimulation caused a median 44% lower expression (0.56-fold, Q1,3 0.51, 0.6, p<0.01) of 
ACTA2 (αSMA gene) in anti-125b transfected cells compared to anti-scr controls with and 
without starvation (Fig. 2A-B), while no difference was observed on the basal levels without 
TGFβ1 stimulation. Accordingly, HC fibroblasts transfected with anti-125b and stimulated 
with TGFβ1 showed a significantly reduced expression of αSMA protein content and fiber 
formation without starvation (Fig. 2C, E) and even stronger reduction with starvation (Fig. 
2D), which was further confirmed in SSc fibroblasts (5.32-fold, Q1,3 3.17, 6.34 in comparison 
with anti-scr 9.05-fold, Q1,3 7.94, 9.9, p<0.01) (Fig. 2F). In addition, miR-125b 
overexpression caused an upregulation of αSMA protein already on the basal level (3.77-fold, 
Q1,3 2.2, 3.82, p<0.01), which increased further after stimulation with TGFβ1 (Fig. 2G).  
     Thus, miR-125b affected αSMA expression on the mRNA and protein level, but did not 
induce collagens. 
RNA deep sequencing unraveled potential pro-apoptotic targets of miR-125b 
     To identify direct targets of miR-125b in the pathogenesis of SSc, we downregulated miR-
125b with antagomirs in HC fibroblasts, mimicking the downregulation observed in SSc skin. 
RNA was isolated 24 hours later and subjected to deep RNA sequencing. For assessing 
differentially expressed genes the following criteria were used: FPKM > 5, fold change > 1.2, 
p-value <0.01 (Suppl. Fig. 6A). In total, 163 genes were differentially expressed (36 
downregulated and 127 upregulated). Further, we performed computational prediction 
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differentially expressed genes. Out of 163 differentially expressed genes, 59 were identified 
as predicted targets of miR-125b, which indicated successful enrichment for miR-125b 
targets in this experimental setting. Hierarchical clustering of predicted targets (Suppl. Fig. 
6B) allowed us to choose consistently upregulated targets for further validation. 
Consequently, BAK1, BMF and BBC3, all members of the mitochondrial apoptotic pathway, 
were identified (Suppl. Table. 5). qPCR showed that at 24, 48 and 72 hours after 
downregulation of miR-125b, all three target genes were consistently upregulated in HC 
fibroblasts (1.21-1.79-fold up, p<0.001) (Fig. 3A). Similarly, these pro-apoptotic genes were 
upregulated 48 and 72 hours after transfection in SSc fibroblasts. At 24 hours, BAK1 and 
BMF were upregulated (1.53 and 1.47-fold change, respectively, p<0.05), but not BBC3 
(1.15-fold, p=0.21) (Fig. 3B). 
     To further support a regulation of BAK1, BMF and BBC3 by miR-125, we next 
overexpressed miR-125b in SSc and HC fibroblasts using pre-miRs. BAK1, BMF and BBC3 
were downregulated 24-72 hours after transfection with downregulation of 0.41-0.74-fold 
(p<0.05) in HC and SSc fibroblasts (Fig. 3C-D). These results indicate that miR-125b 
downregulation and overexpression directly affect the expression of its predicted targets.  
     Among these three genes of interest, BAK1 is the main regulator of apoptosis, while BMF 
and BBC3 play secondary roles in the mitochondrial apoptotic pathway. Based on the qPCR 
data, the miR-125b-dependent regulation of BAK1 gene expression was the most consistent 
among all predicted targets. BAK1 protein expression was upregulated after miR-125b 
downregulation already 48 hours after transfection (median 2.19, Q1,3 1.52, 2.47, p<0.01) and 
showed sustained upregulation up to 72 hours (median 2.28, Q1,3 1.66, 2.51, p<0.01) (Fig. 
4A) in HC fibroblasts. The maximal upregulation of BAK1 in SSc fibroblasts following miR-
125b downregulation was noticed at 72 hours (median 2.61, Q1,3 1.96, 3.76, p<0.01) (Fig. 
4B). Overexpression of miR-125b decreased the expression of BAK1 in HC (median 0.38, 
Q1,3 0.23, 0.48, p<0.05) and SSc fibroblasts (median 0.45, Q1,3 0.22, 0.61, p<0.05) (Fig. 4C), 
indicating direct effects of miR-125b on BAK1 protein expression. 
     To further confirm BAK1 as the main target of miR-125b we analyzed the basal 
expression levels of BAK1 and two other targets (BMF and BBC3) in skin biopsies and 
dermal fibroblasts. We found that BAK1 is significantly upregulated in SSc skin (median 
1.76, Q1,3 1.27, 2.14; n=9, p<0.001) compared with HC skin (n=13) (Fig. 4D), as well as in 
SSc primary dermal fibroblasts (median 1.75, Q1,3 1.14, 3.13; n=13, p<0.05) compared with 
HC fibroblasts (n=10) (Fig. 4E). There was no significant difference in the basal expression 
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     To implicate BAK1 as the main target of miR-125b and as a crucial mediator in apoptosis, 
we downregulated its expression with siRNA in HC and SSc dermal fibroblasts (Suppl. Fig. 
7). We observed a significant reduction of apoptosis assessed by cleaved caspase 3 Western 
blot (Fig. 4F, G) and cleaved caspases 3/7 assay (Fig. 5F, G). These results clearly confirm 
that BAK1 represents a proapoptotic protein in primary dermal HC and SSc fibroblasts.       
 
MiR-125b downregulation increases apoptosis and decreases proliferation 
     We hypothesized that the upregulation of apoptotic genes on the mRNA and protein level 
might influence the apoptosis rate of transfected cells. Accordingly, we performed the 
cleaved caspase 3/7 assay, which detects the cleaved effector caspases 3 and 7, assessing the 
final irreversible step of apoptosis. Since spontaneous apoptosis is a rare event in our 
experimental cell culture set-up, we used camptothecin and staurosporine to induce apoptosis. 
Downregulation of miR-125b increased the rate of apoptosis in cells already 24 hours after 
transfection (median 1.52, Q1,3 1.33, 1.82, p<0.01, Fig. 5A). The higher rate of apoptosis 
persisted up to 72 hours after transfection in HC and SSc fibroblasts. To confirm the effects 
of miR-125b on apoptosis, we overexpressed miR-125b and observed reduced apoptosis 
starting from 24 hours after transfection (median 0.42, Q1,3 0.24, 0.62, p<0.01) up to at least 
72 hours (median 0.45, Q1,3 0.33, 0.7, p<0.01) in HC and SSc fibroblasts (Fig. 5B).  
     To further verify the increased apoptosis in cells transfected with anti-125b, we performed 
Western blot and immunofluorescence staining for cleaved caspase 3. MiR-125b 
downregulation resulted in higher levels of cleaved caspase 3 in comparison with anti-scr 
controls in HC fibroblasts (median 2.29, Q1,3 1.62, 4.02) and in SSc fibroblasts (median 2.21, 
Q1,3 1.19, 4.09, p<0.01) (Fig. 5C-D and Suppl. Fig. 8). Accordingly, overexpression of miR-
125b caused a lower cleaved caspase 3 signal detected by Western blot (Fig. 5E), confirming 
that miR-125b downregulation activates cells to become more prone to undergo apoptosis 
and its overexpression dampens this process.  
     In order to elucidate the main target, through which miR-125b regulates apoptosis, we 
performed double transfection (downregulation of miR-125b expression with anti-125b and 
downregulation of BAK1 expression with siRNA) and further assessed apoptosis by cleaved 
caspases 3/7 assay. As expected, BAK1 downregulation alone decreased level of apoptosis in 
both HC and SSc fibroblasts after 48 hours post transfection. Indeed, double downregulation 
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apoptosis in HC and SSc fibroblasts after 48 (Fig. 5F-G) and 72 hours (Suppl. Fig. 9), 
indicating the crucial role of BAK1 in miR-125b-regulated apoptosis. 
     To further investigate the role of miR-125b in apoptosis, we performed Annexin V live 
staining after anti-125b transfection with and without apoptosis stimulation. Already 5 hours 
after staurosporine (STP)-induced apoptosis, increased signals of annexin V in cells 
transfected with anti-125b in comparison to anti-scr control were observed (Fig. 6A). This 
effect steadily increased for up to 16 hours with significant difference between 7 and 15 
hours (p<0.05) (Fig. 6B).  
     Additionally, we investigated the effects of mir-125b on proliferation of SSc fibroblasts by 
real-time proliferation assay. The cell index was monitored over 160 hours (Fig. 6C) and the 
slope of the exponential growth phase was used to assess proliferation. Following TGFβ1 
stimulation, cells transfected with anti-125b showed decreased levels of proliferation 
compared to anti-scr controls (n=8, p<0.05) (Fig. 6D). Similarly, reduced proliferation was 
also detected by BrdU assay in HC and in SSc fibroblasts after anti-125b transfection 
(median 0.83, Q1,3 0.71, 0.9, p<0.05) (Suppl. Fig. 10). 
     Taken together, miR-125b downregulation, as observed in SSc skin biopsies and dermal 
SSc fibroblasts, increased apoptosis and reduced proliferation in dermal fibroblasts, 
indicating a regulatory role of miR-125b in fibrosis.   
 
DISCUSSION 
     Our study showed that miR-125b is downregulated in the skin and primary dermal 
fibroblasts of SSc patients in comparison to healthy controls. Previously identified, 
downregulated miRs in SSc (let-7a, miR-7, miR-29, miR-133, etc.) directly de-repressed their 
ECM targets, such as collagens, thereby facilitating fibrogenesis(15, 16, 26-28). In contrast, 
we could demonstrate that miR-125b did not directly alter ECM components, namely 
collagens type I, III and V. Conversely, miR-125b downregulation resulted in a significantly 
decreased expression of αSMA, a marker of activated fibroblasts. Following miR-125b 
downregulation, less αSMA-positive fibers were observed, indicating that there is a reduced 
number of αSMA-positive cells, i.e. activated myofibroblasts. Such discrepancy might occur 
due to different molecular mechanisms of collagen production and formation of αSMA-
positive fibers, even though both features usually appear together in emerging fibrosis. 
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that reduced formation of αSMA-positive fibers may be a result of cytoskeleton 
reorganization due to entering pro-apoptotic status by the cells(29, 30) that will be discussed 
later. Thus, while previously identified, differentially expressed miRs in SSc promoted 
fibrosis, here we present a novel role for microRNAs in the pathophysiology of SSc: the 
downregulation of miR-125b in SSc exerts protective counter-regulatory effects on the 
progression of skin fibrosis 
     A recent publication showed that miR-125b was upregulated in cardiac fibrosis and in 
human primary cardiac fibroblasts (HCF)(17). This process was directly regulated by TGFβ1 
and potentiated TGFβ-induced collagen I and αSMA expression. At the same time, 
downregulation of miR-125b in HCF decreased TGFβ-driven collagen I and αSMA 
expression(17). Consistent with these published data, in our studies on dermal fibroblasts, 
downregulation of miR-125b decreased TGFβ-driven αSMA expression on the mRNA and 
protein level, but did not affect collagen I expression. Therefore, while downregulation of 
miR-125b in SSc skin may carry a compensatory, protective role against fibrosis, miR-125b 
upregulation in cardiac fibrosis appears to be pro-fibrotic. Such organ- and disease-specific 
functions are well-known features of miRs in general and specifically for miR-125b, for 
which pro- and anti-apoptotic effects in oncology have been proposed dependent on the 
underlying type of cancer(18).  
     We found that miR-125b expression in primary dermal fibroblasts is independent from 
major cytokines active in SSc. However, it is downregulated by inhibitors of histone 
deacetylases (HDAC), as shown by experiments with TSA (pan-inhibitor of HDAC) and 
TBA (inhibitor of class II HDAC with the greatest selectivity towards HDAC6(31)). Recent 
studies in oncology showed an upregulation of mir-125b by histone deacetylase inhibitors 
again pointing to tissue and disease-specific effects(32-35). Our results indicate the presence 
of an epigenetic repressor of miR-125b, which is activated by HDAC inhibitors. The detailed 
mechanisms underlying these effects need to be elucidated in further studies.   
     The limitation of our study is the lack of sufficient number of site matched healthy 
controls and of the subsets of the disease: lcSSc and dcSSc. Therefore, we used additionally 
unmatched healthy controls for analysis. Despite there may be a distinct gene expression 
pattern on the different sites of the body due to tissue origin and physiological conditions, as 
well as different gene expression signatures in disease subsets, there was no significant 
difference in miR-125b expression between different anatomical sites or between analyses of 
full skin or fibroblasts derived from lcSSc and dcSSc. These data allowed us to use also 
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     To identify direct targets of miR-125b, we performed RNA deep sequencing that revealed 
BAK1, BMF and BBC3 as potential predicted targets. Of note, all three consistently 
upregulated genes belong to the mitochondrial apoptotic pathway. Validation by qPCR 
showed that the downregulation of miR-125b increased the expression of these genes, 
whereas miR-125b overexpression resulted in their downregulation. These observations 
further support a direct functional regulation by miR-125b. Among the three genes of 
interest, BAK1 had the strongest induction after miR-125b downregulation. Additionally, 
miR-125b overexpression led to downregulation of BAK1 protein both in HC and SSc 
fibroblasts. These results are further supported by other studies indicating a direct regulation 
of BAK1 by miR-125b(36-40). 
     One of the proposed mechanisms driving fibrosis in SSc and other related diseases is a 
lack of adequate fibroblast apoptosis(4). However, there is an incomplete understanding of 
the detailed mechanism underlying the activation of apoptosis during dermal fibrogenesis. 
Potential therapeutic strategies might be based on promoting apoptosis of pathological dermal 
myofibroblasts(41). We showed that miR-125b downregulation increases apoptosis, and that 
miR-125b upregulation decreases apoptosis, indicating the functional significance of miR-
125b in the regulation of apoptosis in dermal fibroblasts. Furthermore, we showed by real-
time proliferation assay and BrdU assay that miR-125b downregulation reduced cell 
proliferation in dermal fibroblasts, which is supported by studies in cancer (18, 42). However, 
if considered as an anti-fibrotic therapy, tissue and cell-specific differences of miR-125 will 
have to be addressed. 
     In conclusion, to our knowledge this is the first evidence that downregulation of a single 
miR in SSc has protective effects on disease progression. Downregulation of miR-125b may 
have compensatory protective effects directed against excessive skin fibrosis by (1) 
decreasing the number of αSMA-positive cells; (2) increasing apoptosis; and (3) decreasing 
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Figure 1. Downregulation of miR-125b in skin samples and primary dermal fibroblasts. 
A. MiR-125b expression in skin biopsies from healthy controls (HC) and SSc patients (n=10 
each, black triangles indicate dcSSc subset). B. Basal expression of miR-125b in cultured 
primary dermal fibroblasts from HC and SSc (n=10 each). C-H. Histone deacetylase 
inhibitors (HDAC) regulate miR-125b expression. C. HC fibroblasts (n = 5) and D. SSc 
fibroblasts (n=5) were stimulated with different doses of HDAC inhibitor trichostatin A 
(TSA) for 24 hours. E. HC (n = 6) and F. SSc fibroblasts (n=5) were stimulated with 2µM 
TSA for up to 72 hours. G. HC fibroblasts (n = 7) and H. SSc fibroblasts (n=7) were 
stimulated with different doses of HDAC inhibitor tubastatin A (TBA) for 24 hours. I-J. 
Effect of TBA on the expression of unrelated miR-342. I. HC (n = 7) and J. SSc fibroblasts 
(n=7) were stimulated with different doses of TBA for 24 hours. Red lines represent 
respective controls and red dashed lines represent the median level of miR-125b 
downregulation in SSc fibroblasts. A-J. Data are presented as median ± interquartile range. 
***p<0.001, **p<0.01, *p<0.05, ns – not significant, A-B. ***p < 0.001, Mann-Whitney 
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Figure 2. αSMA expression is regulated by miR-125b after TGFβ stimulation. A-B. 
ACTA2 mRNA expression after transfection with anti-125b and TGFβ (10ng/ml) stimulation 
in HC fibroblasts A. without (n=6) and B. with starvation (n=5). RNA was harvested 4 days 
after transfection, 3 days of starvation (only B) and 2 days of TGFβ stimulation. C–D. 
Representative pictures of Western blot and semi-quantification with densitometry analyzed 
by ImageJ for αSMA from HC fibroblasts C. without starvation (n=6) and D. with starvation 
(n=6) 5 days after transfection, 4 days of starvation (only D) and 3 days of TGFβ stimulation 
(C-D). Data are presented as median ± interquartile range. ns – not significant, *p<0.05, 
Mann-Whitney test. E. αSMA immunofluorescence after transfection with anti-125b and 
TGFβ stimulation in HC fibroblasts (n=4). Red – αSMA, blue – DAPI. Scale bar 100 µm. F – 
G. Representative pictures of Western blot and semi-quantification with densitometry 
analyzed by ImageJ for αSMA from SSc fibroblasts transfected F. with anti-125b (n=8) and 
G. pre-125b (n=5) 5 days after transfection, 4 days of starvation and 3 days of TGFβ 
stimulation. Data are presented as median ± interquartile range. ns – not significant, 
**p<0.01, Mann-Whitney test. 
Figure 3. MiR-125b regulates the expression of its pro-apoptotic targets BAK1, BMF 
and BBC3. A. BAK1, BMF and BBC3 mRNA expression 24, 48 and 72 hours after 
transfection with anti-125b in HC fibroblasts (n=12 for each time point). B. BAK1, BMF and 
BBC3 mRNA expression 24, 48 and 72 hours after transfection with anti-125b in SSc 
fibroblasts (n=12 for each time point). C. BAK1, BMF and BBC3 mRNA expression 24, 48 
and 72 hours after pre-125b transfection in HC fibroblasts (n=12 for each time point). D. 
BAK1, BMF and BBC3 mRNA expression 24, 48 and 72 hours after pre-125b transfection in 
SSc fibroblasts (n=12 for each time point). Data are presented as median ± interquartile 
range. Red lines represent respective anti-scr controls. ***p<0.01, **p<0.01, *p<0.05, ns – 
not significant, Wilcoxon signed rank test.  
Figure 4. MiR-125b regulates pro-apoptotic BAK1 protein expression. Representative 
pictures of Western blot and semi-quantification with densitometry analyzed by ImageJ for 
BAK1 from A. HC (n=10) and B. SSc (n=10) fibroblasts (48 hours after transfection with 
anti-125b). C. Representative pictures of Western blots and semi-quantification from HC 
(n=6) and SSc (n=8) fibroblasts 48 hours after transfection with pre-125b. Data are presented 
as median ± interquartile range. Red lines represent respective controls. **p<0.01, *p<0.05, 
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patients (n=9). E. Basal expression of BAK1 in cultured primary dermal fibroblasts from HC 
(n=10) and SSc (n=13). *p<0.05, ***p < 0.001, Mann-Whitney test. F-G. Western blot for 
cleaved caspase 3. Representative pictures of Western blot and semi-quantification by ImageJ 
for cleaved caspase 3 from F. HC (n=7) and G. SSc (n=7) fibroblasts transfected with BAK1 
siRNA. Data are presented as median ± interquartile range. Red lines represent respective 
controls. *p<0.05, Wilcoxon signed rank test. 
 
Figure 5. Cleaved caspases 3/7 is regulated by miR-125b and BAK1. A-B. Analysis of 
cleaved caspases 3/7 measured by Real-Glo® assay. A. Camptothecin (CPT) induced 
apoptosis 24, 48 and 72 hours after anti-125b transfection in HC (n=10) and in SSc 
fibroblasts (n=9). B. CPT-induced apoptosis 24, 48 and 72 hours after transfection with pre-
125b in HC (n=10) and in SSc fibroblasts (n=9). 200µM CPT was added 18 hours before the 
assay to induce apoptosis.   C-E. Western blot for cleaved caspase 3. C-D. Representative 
pictures of Western blot and semi-quantification by ImageJ for cleaved caspase 3 from C. HC 
(n=10) and D. SSc (n=10) fibroblasts transfected with anti-125b. E. Representative pictures 
of Western blot and semi-quantification from HC (n=3) and SSc (n=3) fibroblasts transfected 
with pre-125b; significance is not tested due to low n. F-G. Cleaved caspases 3/7 assay in F. 
HC (n=8) and in G. SSc fibroblasts (n=7). CPT induced apoptosis was assessed 48 hours 
after double anti-125b and BAK1 siRNA transfection. A-G. Data are presented as median ± 
interquartile range and normalized to respective scrambled control. Red lines represent 
respective controls.  ***p<0.01, **p<0.01, *p<0.05, Wilcoxon signed rank test. 
 
Figure 6. MiR-125b activates apoptosis with the reduction of cell proliferation. A. 
Representative picture of annexin V live measurements normalized to anti-scr. B. Statistical 
analysis of annexin V live measurements (n=6 SSc) for each time point recorded (every 70 
min) after anti-125b transfection normalized to respective anti-scr controls (represented by 
the red line). Data are presented as median ± interquartile range. *p<0.05, ns – not 
significant, Wilcoxon signed rank test. C. Representative picture of real-time proliferation 
assessed by cell index normalized to the time point of transfection. D. Slope was used to 
assess the proliferation (n=8, SSc fibroblasts). Data are presented as median ± interquartile 
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